Acute Social Anxiety Disorder Market

• The Acute Social Anxiety Disorder market is anticipated to sustain a steady Compound Annual Growth Rate (CAGR) from 2024 to 2034. This growth in market revenue is chiefly propelled by advancements in diagnostic techniques, heightened awareness of the condition, and a growing number of reported cases.
• Social anxiety disorder cases are increasing due to several factors including genetic mutation, among others. 
• In the realm of anxiety disorders, numerous unmet needs persist, ranging from the necessity for medications that are more efficacious, fast-acting, and better tolerated to the early identification of nonresponse.
• The absence of FDA-approved treatments and the limited options available create ample growth opportunities for the future market. As research advances and innovative therapies emerge, there is significant potential for expansion in addressing the unmet needs of patients with social anxiety disorder.
• To drive the acute social anxiety disorder market in future years, several companies including Vistagen Therapeutics, Bionomics, EmpowerPharm, and others are developing their assets in the mid-late stage of development. With the expected approval of these therapies during the forecast period [2024–2034], the overall therapeutic market of acute social anxiety disorder is likely to witness a rise at a significant CAGR.

DelveInsight’s comprehensive report titled “Acute Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast 2034” offers a detailed analysis of acute social anxiety disorder. The report presents historical and projected epidemiological data covering Total Prevalent Cases and Diagnosed Prevalent Cases of Acute social anxiety disorder further segmented by Gender, Age, and Severity. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in acute social anxiety disorder. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Acute Social Anxiety Disorder Treatment Market

Social Anxiety disorder (also called Social Phobia; SAD) is the most common mental health condition that causes extreme fear in social settings and an intense, persistent fear of being watched and judged by others.

People with social anxiety disorder have trouble talking to people, meeting new people, attend social gatherings which can also affect day-to-day activities.

Social anxiety disorder can make a person fear of being judged or scrutinized by others. Patients may understand that their fears are irrational or unreasonable, but feel powerless to overcome them.

Social anxiety is different from shyness which is usually short-term and doesn’t disrupt one’s life. Social anxiety is persistent and debilitating. It can affect one’s ability to work, attend school, and develop close relationships with people outside of their family.

Symptoms of Social Anxiety disorder may include physical symptoms which can be blushing, nausea, excessive sweating, trembling or shaking, difficulty in speaking, dizziness or lightheadedness, and rapid heart rate.

It can also include several psychological symptoms which are worrying intensely about social situations, worrying for days or weeks before an event, avoiding social situations or trying to blend into the background, worrying about embarrassing themselves in a social situation, worrying that other people will notice them stressed or nervous, and needing alcohol to face a social situation.

Acute Social Anxiety Disorder Diagnosis and Treatment Algorithm 

There are no medical tests to check for social anxiety disorder and the healthcare provider diagnoses the social phobia from a description of symptoms. They can also diagnose social phobia after examining behavioral patterns. 

The diagnosis of SAD is based on the DSM-5. The patient must have a marked, persistent fear of, or anxiety about one or more social situations in which they may be judged by others. The symptoms must persist for 6 or more months. The fear must involve thoughts of humiliation, embarrassment, rejection, or offensiveness. Other factors which should be present are:

• The same social situations nearly always trigger anxiety or fear.
• The patient actively avoids these situations.
• The anxiety or fear is out of proportion to the actual threat, considering normal sociocultural factors.
• The anxiety, fear, and/or avoidance cause significant distress or greatly impair social or occupational functioning.

The final diagnostic factor is that the anxiety and fear cannot be more correctly characterized as a different mental disorder, such as agoraphobia, body dysmorphic disorder, or panic disorder.

Treatment options for social anxiety disorder may include cognitive behavioral therapy, exposure therapy, group therapy, anti-anxiety medications, anti-depressants, and beta-blockers.

According to the National Institute of Health and Clinical Excellence (NICE) guidelines for Social anxiety disorder, the treatment includes psychological and pharmacological options. The psychological intervention termed cognitive-behavioral therapy (CBT) is used to help patients face barriers directly through exposure techniques, relaxation techniques, and training in social and conversational skills. It is always recommended that CBT should be always implemented ahead of pharmacologic therapy. Patients who manage their symptoms with psychological and pharmacologic treatment are more likely to achieve continued symptom-improvement benefits.

Currently, there is no approved medication for the treatment of acute anxiety in individuals with SAD. SAD is typically treated on a long-term basis using FDA-approved antidepressants with a sluggish onset of action (weeks) and limited therapeutic effects, as well as benzodiazepines, which are not FDA-approved for the treatment of SAD but are recommended for off-label usage. 

Once the patient attains the desired therapeutic response, the medication should be continued for at least 12 months to prevent relapse. Selective Serotonin reuptake inhibitors (SSRIs), Serotonin-norepinephrine reuptake inhibitors (SNRIs), Monoamine Oxidase Inhibitors (MAOIs), Gamma-aminobutyric acid (GABA), Beta-Blockers, and other anxiolytics are the standard drug classes used to treat SAD.

Acute Social Anxiety Disorder Epidemiology

The epidemiology section on the acute social anxiety disorder market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of acute social anxiety disorder. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• During the acute social anxiety disorder analysis, it was found that social anxiety disorder affects around 15 million adults or 6.8% of the US population. 
• The prevalence rate of SAD was found to be higher in women (15.5%) as compared to men (11.1%) in the US.
• In the analysis, it was found that the lifetime prevalence of social anxiety disorder in the general population was close to 7% in Europe. It was found that the lifetime prevalence of social anxiety disorder is approximately 12% in the UK population.
• During the analysis, it was found that 36% of people with social anxiety disorder experience symptoms for 10 years or more before seeking care.
• The analysis observed that the prevalence of Taijin kyofusho (Japanese form of Social Phobia) in Japan is approximately between 10-20% in general population and it is somewhat more common in men than women.
• The epidemiology of acute social anxiety disorder is expected to change during the forecast period (2024-2034).

Acute Social Anxiety Disorder Market Outlook

The acute social anxiety disorder therapeutics market is further expected to increase by the major drivers, such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period [2024–2034].

In November 2015, Japan Ministry of Health, Labour, and Welfare (MHLW) approved LEXAPRO for the treatment of social anxiety disorder.

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the acute social anxiety disorder market in the 7MM is expected to change significantly during the study period 2020–2034.

Acute Social Anxiety Disorder Drug Chapters 

Marketed Acute Social Anxiety Disorder Drugs

LEXAPRO: Mochida Pharmaceutical/Lundbeck

LEXAPRO is a selective serotonin reuptake inhibitor (SSRI) antidepressant indicated for the treatment of social anxiety disorder. Lexapro is originated by H. Lundbeck. Mochida started the development in Japan under a license from Lundbeck in 2002 and obtained the manufacture and marketing approval of LEXAPRO with the indication for treatment of depression/depressive state in 2011.

Note: Detailed marketed therapies assessment will be provided in the final report.

Emerging Acute Social Anxiety Disorder Drugs

The acute social anxiety disorder market is expected to experience gradual changes, mainly due to the limited availability of emerging therapies in this area. Key market players, Vistagen Therapeutics, Bionomics, EmpowerPharm, and others have demonstrated a keen interest in this condition and are actively pursuing the development of potential treatments.

PH94B: Vistagen Therapeutics

Vistagen Therapeutics is currently developing its lead product candidate PH94B nasal spray which is fundamentally different from all current drug treatments for SAD. PH94B binds to nasal chemosensory receptors which activates neural circuits that lead to rapid suppression of fear and anxiety. The US FDA has granted Fast Track designation for the development of PH94B for the acute treatment of anxiety in adults with SAD. In August 2023, the company announced positive top-line results from its Phase III PALISADE-2 trial of fasedienol (PH94B) nasal spray in adults diagnosed with SAD. To complement the positive results from PALISADE-2, Vistagen is preparing to launch two similar Phase III clinical trials in 2024.

BNC210: Bionomics

BNC210 is a selective NAM of the α7 receptor being developed for the treatment of Social Anxiety Disorder. The study is to assess the effects of an acute dose of BNC210 compared to placebo on reducing anxiety provoked by a speaking challenge and measured using the Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD). BNC 210 is a Bionomics proprietary molecule in development for the treatment of SAD, post-traumatic stress disorder (PTSD), and anxiety disorders. It has a novel mechanism of action and extensive clinical and non-clinical studies have shown several properties which may be useful to treat SAD. Additionally, in December 2021, BNC210 received fast-track designation from the US FDA. The drug has completed the Phase II clinical trial for the treatment of social anxiety disorder.

EPI-CBD-001: EmpowerPharmBPX-01: Timber Pharmaceuticals/BioPharmX

EPI-CBD-001 is a cannabidiol oral solution being developed by EmpowerPharm in a Phase II, randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety, and tolerability of patients with Social Anxiety Disorder. The Phase II study is expected to enroll 225 patients at 22 clinical centers in the United States and be completed by September 2023. Previously, in May 2022, the company received clearance from the US FDA for a Phase II trial.

Acute Social Anxiety Disorder Market Segmentation

DelveInsight’s ‘Acute Social Anxiety Disorder – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future acute social anxiety disorder market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies. 

Acute Social Anxiety Disorder Market Size by Countries

The acute social anxiety disorder market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2023, the United States held a significant share of the overall 7MM (Seven Major Markets) acute social anxiety disorder market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Acute Social Anxiety Disorder Market Size by Therapies

Acute social anxiety disorder Market Size by Therapies is categorized into current and emerging markets for the study period 2020–2034. One of the emerging drugs anticipated to launch during the forecast period is PH94B under the developmental pipeline of Vistagen Therapeutics.

Acute Social Anxiety Disorder Drugs Uptake

This section focuses on the sales uptake of potential acute social anxiety disorder drugs that have recently been launched or are anticipated to be launched in the acute social anxiety disorder market between 2020 and 2034. It estimates the market penetration of acute social anxiety disorder drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the acute social anxiety disorder market.

The emerging acute social anxiety disorder therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the acute social anxiety disorder market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on acute social anxiety disorder.

Acute Social Anxiety Disorder Market Access and Reimbursement

DelveInsight’s ‘Acute Social Anxiety Disorder – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of acute social anxiety disorder.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments. 

KOL Views

To keep up with current acute social anxiety disorder market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the acute social anxiety disorder domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or acute social anxiety disorder market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the acute social anxiety disorder unmet needs.

Acute Social Anxiety Disorder: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as New York State Psychiatric Institute and Columbia University in the US, Clinical Psychology, Pace University in the US, Department of Psychosomatics and Psychotherapy, Justus-Liebig-University Giessen in Germany, Anxiety and Depression Association of America, among others.

“Social anxiety disorder (SAD) is a debilitating and chronic illness characterized by persistent fear of one or more social or performance situations.”

“Over the past two decades, research on SAD has accumulated. Unfortunately, the terminology has not remained static over time.”

“The lack of robust pipeline, social discrimination, low clinical drug development success rate, and lack of healthcare specialist might hinder the market growth of SAD.”

Note: Detailed assessment of KOL Views will be provided in the full report on acute social anxiety disorder.

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the acute social anxiety disorder Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Acute Social Anxiety Disorder Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for acute social anxiety disorder. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, patent details, and other information for emerging acute social anxiety disorder therapies.

Acute Social Anxiety Disorder Market Report Insights

• Acute social anxiety disorder Patient Population
• Acute Social Anxiety Disorder Therapeutic Approaches
• Acute social anxiety disorder Pipeline Analysis
• Acute social anxiety disorder Market Size and Trends
• Acute social anxiety disorder Market Opportunities
• Impact of Upcoming Acute Social Anxiety Disorder Therapies

Acute Social Anxiety Disorder Market Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• Acute social anxiety disorder Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Acute social anxiety disorder Market
• Acute Social Anxiety Disorder Drug Uptake

Acute Social Anxiety Disorder Market Report Assessment

• Acute social anxiety disorder Current Treatment Practices
• Acute Social Anxiety Disorder Unmet Needs
• Acute social anxiety disorder Pipeline Product Profiles
• Acute social anxiety disorder Market Attractiveness

Key Questions

• How common is acute social anxiety disorder?
• What are the key findings of acute social anxiety disorder epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020–2034)?
• What are the currently available treatments for acute social anxiety disorder?
• What is the disease risk, burden, and unmet needs of acute social anxiety disorder?
• At what CAGR is the acute social anxiety disorder market and its epidemiology is expected to grow in the 7MM during the forecast period (2024–2034)?
• How would the unmet needs impact the acute social anxiety disorder market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of acute social anxiety disorder in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2024–2034)?
• How many companies are currently developing therapies for the treatment of acute social anxiety disorder?